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 14 
ABSTRACT 15 
Calixarenes are promising scaffolds for an efficient clustered exposition of multiple saccharide antigenic 16 
units. Herein we report the synthesis and biological evaluation of a calix[6]arene functionalized with six 17 
copies of the trisaccharide repeating unit of Streptococcus pneumoniae (SP) serotype 19F. This system has 18 
demonstrated its ability to efficiently inhibit the binding between the native 19F capsular polysaccharide 19 
and anti-19F antibodies, despite a low number of exposed saccharide antigens, well mimicking the epitope 20 
presentations in the polysaccharide. The calix[6]arene mobile scaffold has been selected for 21 
functionalization with SP 19F repeating unit after a preliminary screening of four model glycocalixarenes, 22 
functionalized with N-acetyl mannosamine, and differing in the valency and/or conformational properties. 23 
This work is a step forward towards the development of new fully synthetic calixarenes comprising small 24 
carbohydrate antigens as potential carbohydrate-based vaccine scaffold. 25 
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1. INTRODUCTION: 29 
Encapsulated bacterial infections are still one of the most prevalent causes of serious disease in humans, 30 
especially in young children. Immunization is the most appropriate way to prevent bacterial infections [1]. 31 
In the early stages of microbiology, capsular polysaccharides (CPSs) were recognized as relevant virulence 32 
factors, and found to be able to stimulate protective immunity against infections, laying the bases for the 33 
development of current antibacterial vaccines [2]. Nevertheless, the study of the chemical determinants of 34 
immunogenicity to CPSs still requires detailed molecular insights. CPSs are cell-surface polymers consisting 35 
of oligosaccharide repeating units, characterized by a huge number of possible structural modifications and 36 
linkage combinations and associated to a relative high degree of flexibility. Typically, anti-carbohydrate 37 
antibodies show affinities in their recognition that are several factors lower than those observed for 38 
antibodies specific for proteins or peptide antigens. This peculiar weakness is partially compensated by the 39 
multivalent nature of such antibodies, that face in a clustered form a multiple number of densely displayed 40 
antigen molecules to increase the effect of the response [3]. This can explain the existing relationship 41 
between molecular weight and antigenicity, established for polysaccharide antigens. In fact, high molecular 42 
mass repetitive polysaccharides are able to simultaneously display a greater number of epitopes capable to 43 
effectively interact with specific antibodies. This kind of model where the binding of a glycan-binding 44 
protein to a clustered saccharide patch enhances the overall affinity of the interaction has been widely 1 
described [4], for instance between tumor associated saccharide antigens and lectins. Lectin-glycan 2 
interactions are stabilized by weak hydrogen bonding and van der Waals intermolecular forces, and the 3 
multivalent presentation is the basis for a biologically relevant binding. There are several examples 4 
demonstrating that lectins bind their targets only when glycans are clustered at high density in a 5 
multivalent glycoconjugate backbone [5]. This concept has been exploited for instance in the field of cancer 6 
vaccine development. For example, the Tn tumor associated antigen is overexpressed on the surface of 7 
tumor cells. It is exposed on the Mucine surface in clusters of 2 to 5 units. Data show that at least two 8 
contiguous antigen molecules are crucial for the binding of the anti-Tn monoclonal antibodies, with an even 9 
greater affinity in the presence of three residues [6]. Different studies have been oriented to the selection 10 
of the proper scaffold for the presentation of multiple copies of the Tn antigenic unit to generate an 11 
anticancer vaccine [7, 8, 9]. The choice of the scaffold for multivalent presentation of glycans to target 12 
proteins is crucial in determining the biological activity [10, 11, 12, 13]. In this context, the use of 13 
calixarenes represents a viable approach explored in the literature for the display of multiple glycan units 14 
[14]. This type of macrocycle in fact, due to peculiar structural properties and selective synthetic 15 
procedures [15], allows the achievement of small libraries of potential multivalent ligands bearing the same 16 
epitopes but with a controlled modulation of their number (valency) and orientation in the space. The 17 
conformational behavior of the different possible types of calixarenes strongly impacts on the presentation 18 
mode of the conjugated saccharide moieties [14, 16], which can be exploited to increase the avidity of the 19 
biological recognition. This versatility can make possible the comparison of subtly modified parameters and 20 
their effects on selectivity and efficiency in biological activities like interaction with carbohydrate 21 
recognition proteins [14]. A calix[4]arene in the so called cone geometry conjugated to LacNAc fragments, 22 
for example, was found extremely selective in the inhibition of galectin-3 while totally unable to bind to 23 
galectin-1 [17]. Calixarenes functionalized with lactose units showed inhibition activity towards human 24 
galectins characterized, in some cases, by an impressive selectivity strictly dependent on their 25 
conformational properties and related arrangement of the epitopes [18]. Analogously, different sized and 26 
conformationally featured calixarenes exposing galactose units resulted in different efficiency in the 27 
binding to Pseudomonas aeurginosa lectin A (PA-IL) [19]. Ten years ago, a calix[4]arene decorated with four 28 
Tn units has indeed been described as a promising synthetic multivalent vaccine candidate [20]. In this 29 
framework, we have decided to explore the potential of calixarenes as scaffolds for the multipresentation 30 
of bacterial CPS fragments. Our hypothesis was to verify if such macrocyclic scaffold, presenting multiple, 31 
but however limited copies of short CPS fragments, is able to gain affinity and potency towards the natural 32 
antibodies approaching those observed for the natural polysaccharide. In principle, a positive assessment 33 
would open the possibility to work with shorter saccharide fragments, which can be obtained by chemical 34 
synthesis, instead of the longer oligosaccharides, used in vaccine formulations, obtained by size-reduced 35 
purified natural polysaccharides [21]. Moreover, the use of calixarenes and short saccharide fragments 36 
would have the advantage of giving structurally well-defined and easily reproducible systems. 37 
We focused on the gram positive bacterium Streptococcus pneumoniae (SP) which is among the major 38 
responsible of severe forms of bacterial infectious diseases [1, 22, 23, 24]. In particular, serotype 19F 39 
(SP19F) is one of the most common causes of invasive pneumococcal disease in children, and included in 40 
the current commercial pneumococcal conjugate vaccines. Its CPS is a linear polymer made up of -D-41 
ManpNAc-(14)--D-Glcp-(12)--L-Rha trisaccharide repeating units, linked through phosphodiester 42 
bridges (Figure 1). Herein, we report on the preparation and biological evaluation of a family of calixarenes 43 
functionalized with saccharide fragments related to the trisaccharide repeating unit of SP19F with the aim 44 
to explore the effect of the multipresentation of the ligand mediated by calixarenes on the binding to the 45 
antibodies. We found that a calix[6]arene, functionalized with six copies of the trisaccharide repeating unit 46 
of SP19F, is capable to effectively inhibit the binding between the native 19F CPS and the anti-19F 47 
antibodies. 48 
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Figure 1: Streptococcus pneumoniae 19F capsular polysaccharide repeating unit 2 
 3 
2. RESULTS AND DISCUSSION 4 
 5 
2.1. Chemistry 6 
We report the synthesis of a small library of glycocalixarenes (compounds 1a-d and 2a-b, Figure 2) 7 
functionalized at the upper rim with saccharide units present in the CPS structure of SP19F. To this aim, 8 
both calix[4]- and calix[6]arenes were selected as scaffolds in order to have a modulation of the valency. 9 
Moreover, the calix[4]arene based derivatives were designed with three different conformational features, 10 
one conformationally mobile, one blocked in the cone geometry, one blocked in the 1,3-alternate one, in 11 
order to compare a different spatial arrangement of the epitope units. Also the calix[6]arene based 12 
glycoclusters are conformationally mobile. In addition, a monovalent acyclic analogue was planned to have 13 
a reference for verifying the role of the multivalency in the interaction with the antibodies. 14 
In a first step of the project, all the selected scaffolds were functionalized with the N-acetyl-β-D-15 
mannosamine residue (compounds 1a-d and 1-MON, Figure 2), while subsequently, based on a preliminary 16 
set of inhibition studies, only the calixarene scaffold of the best inhibitor of the binding between the 19 F 17 
polysaccharide and the corresponding anti-19F antibodies was functionalized with the SP19F trisaccharide 18 
repeating unit. Thus, two additional glycocalixarenes (2a and 2b, Figure 2), were obtained, with increased 19 
similarity with respect to the natural structure. This two-steps approach was pursued because of the 20 
demanding synthesis of the trisaccharide and the consequent difficulty in producing a sufficient amount for 21 
the functionalization of all the available structures. 22 
 1 
Figure 2. Library of multivalent glycocalixarenes decorated with saccharide units of SP 19F CPS  2 
In order to have an efficient and clean reaction for the coupling between the calixarene scaffolds and the 3 
sugar units, we decided to exploit the amine-isothiocyanate condensation. To this aim, the calixarene 4 
isothiocyanates 4a-d and the sugar unit 6, functionalized at the reducing end with an aminopropyl linker, 5 
were synthesized (Scheme 1). Compounds 4a-d were prepared by treatment of the corresponding, already 6 
known aminocalixarenes 3a-d [25, 26, 27] with thiophosgene (caution) in the presence of a base, the cone 7 
isomer following a previously reported procedure [28] and the others through equivalent strategies. It may 8 
be interesting to underline that for the conformationally mobile tetra-isothiocyanate calixarene 4a the 1H 9 
NMR spectrum in CDCl3 highlighted the presence of two conformers, identified as the cone and the partial 10 
cone, in equilibrium and in slow exchange on the NMR timescale, in a 1:4 ratio. 11 
 1 
Scheme 1. Synthesis of glycocalix[n]arenes 1a-d. 2 
 3 
On the basis of procedures reported in the literature [29], we then prepared compound 6, a protected 4 
derivative of 3-aminopropyl N-acetyl-β-D-mannosamine, benzylated at the sugar hydroxyls. 5 
Monosaccharide 6 was deprotected from the Cbz group by hydrogenolysis producing the amino derivative 6 
7 that was subsequently reacted with cone and 1,3-alternate tetra-isothiocyanate calix[4]arenes 4b and 4c, 7 
obtaining in good yields the corresponding tetraglycosylated macrocycles (see SI). Nevertheless, 8 
unexpectedly, their deprotection from benzyl groups to give the two planned glycoclusters failed, despite 9 
the use of different methods, discouraging the use of this pathway for the preparation of the target 10 
calixarenes 1a-d.  11 
Therefore, we went back to monosaccharide 6 to replace benzyl protecting groups with acetyls being 12 
proved that the latter one can efficiently be removed from saccharide units attached to a calixarene 13 
scaffold [13, 14, 30, 31]. Therefore, a sequence of protection and deprotection reactions starting from 6 14 
was carried out to finally obtain compound 11 with an overall yield of 50% (Scheme 2). 15 
 16 
  1 
Scheme 2. Sequence of protection and deprotection steps to obtain compound 11. 2 
More in detail, after the selective removal of N-Cbz from 6 by hydrogenolysis, compound 7 was protected 3 
with a Boc group to give 8. The subsequent catalytic hydrogen transfer under MW irradiation yielded 9, 4 
fully deprotected on the OH groups, without the need of purification. The acetylation step, performed with 5 
acetic anhydride and pyridine, afforded in high yield sugar 10, which was treated with trifluoroacetic 6 
anhydride to remove the Boc group providing 11 in quantitative yield.  7 
The mannosamine derivative 11 was then reacted with the isothiocyanate calixarenes 4a-d. The click 8 
chemistry reaction between isothiocyanate and amine, used for the conjugation reaction, is one of the 9 
most commonly employed methodology for the design and synthesis of multivalent glycoconjugates [32, 10 
33]. This methodology does not involve the anomeric position of the glycoside and the newly formed 11 
thioureido unit presents an enhanced potential for hydrogen bonding that can increase both the solubility 12 
in water of the ligand and the number of interactions with the receptor. Glycocalixarenes 5a [34], 5b, 5c 13 
[34] and 5d were obtained in moderate yields (from 25% to 71%) after column chromatography performed 14 
to remove the sugar excess and traces of partially functionalized derivatives. Finally, compounds 5a-d were 15 
deacetylated under Zemplen conditions at 0 °C to give the target calixarenes 1a-d. For the two 16 
conformationally mobile derivatives 1a and 1d, we proceeded in the investigation by 1H NMR spectroscopy 17 
of their behavior in solution. The 1H NMR spectrum in MeOD of the former one did not give any clear 18 
information about the conformation adopted by the calixarene in solution. A spectrum in D2O was then 19 
recorded, knowing that conformationally mobile calix[4]arene amphiphiles usually tend to adopt in water a 20 
1,3-alternate geometry which minimizes the lipophilic surfaces exposed to the solvent [35]. At room 21 
temperature the spectrum still presented broad signals, difficult to assign, while by raising the temperature 22 
up to 80 °C a rather well-defined spectrum was obtained (see SI at page SI19). It was possible to identify the 23 
signals of the H1 and H2 protons of the sugar moiety, at 4.69 and 4.43 ppm respectively, and, at the same 24 
time, the single signal at around 7 ppm for all the aromatic protons together with the absence of the typical 25 
doublets for the methylene bridge of cone and partial cone conformers demonstrated the adoption of a 26 
1,3-alternate geometry. This should plausibly be the geometry adopted by glycocalixarene 1a also in the 27 
aqueous environment of the biological tests.  28 
As observed for 1a, the 1H NMR spectrum in D2O at room temperature of calix[6]arene 1d was 29 
characterized by broad signals that became sharp by increasing the temperature at 80 °C (see SI at pag 30 
SI25). This behaviour could be explained with the low mobility of the aromatic units through the 31 
macrocyclic annulus, slowed down by the steric hindrance of the bulky substituents at the upper rim 32 
despite the bigger size of the macrocycle. On the other hand, interestingly, in the past it was observed, 1 
rather unexpectedly, that methoxyglucocalix[6]- and [8]arenes tend to self-assemble in aqueous solution 2 
[36], despite the absence of a well-defined amphiphilicity, as indeed for 1a and 1d. For glycocalixarenes 1a 3 
and 1d self-aggregation cannot then be excluded, determining or at least contributing to the broadening of 4 
the signals in the 1H NMR spectrum. In both cases, the sharpening of the signals by increasing the 5 
temperature can be read as a consequence of the assembly disaggregation and/or of the increased mobility 6 
of these derivatives in solution. 7 
Following a similar synthetic strategy, monomeric derivative 1-MON was prepared (Scheme 3) starting from 8 
4-propoxyaniline 12 that was transformed into the corresponding isothiocyanate 13. Compound 13 was 9 
then reacted with sugar unit 11 to give compound 14 which was subsequently deprotected to the final 1-10 
MON in 78% yield.  11 
 12 
Scheme 3. Synthesis of monomer 1-MON 13 
On the basis of the results obtained from biological tests on compounds 1a-d (see below), the 14 
conformationally mobile calix[6]arene was selected as the best scaffold for obtaining the glycocalixarenes 15 
displaying the trisaccharide repeating unit of SP19F. To this aim, exploiting our expertise in the synthesis of 16 
synthetic fragments of Streptococcus pneumoniae [37, 38, 39], we planned the preparation of compound 17 
15, the peracetylated derivative of the SP19F trisaccharide repeating unit, functionalized at the 18 
downstream residue with an amino propyl linker. Compound 15, was synthesized starting from the 19 
trisaccharide trichloroacetimidate donor 16 [37], which was glycosylated with Z-aminopropanol (Scheme 4) 20 
[38]. The reaction was promoted with trimethylsilyl triflate and trisaccharide 17 was obtained in high yields 21 
(96%) as an alpha/beta mixture of the two anomers 17 and 17, which were separated by flash 22 
chromatography. Each anomer was separately subjected to initial exchange of the CBZ amino protecting 23 
group of the linker for the BOC one, followed by hydrogenolysis of the benzyl ethers, and final acetylation 24 
of the hydroxyl groups with acetic anhydride. This protecting group manipulation sequence was very 25 
efficient and allowed to recover in both cases the final trisaccharides 15 and 15 in 88% yield.  26 
 1 
Scheme 4 2 
 3 
Hexaisothiocyanate 4d was separately reacted in good yields with both the  and the  anomer of 4 
compound 15, to evaluate if a different stereochemistry of the anomeric position on the rhamnose residue 5 
may have an influence on the biological activity of the glycocalixarene. If not, in perspective, the calixarene 6 
could be reacted with the mixture of the two anomers that is produced in the final step of the synthesis of 7 
the trisaccharide when the aminopropyl chain is introduced at the anomeric position of rhamnose. The two 8 
glycocalixarenes 18a and 18b obtained by this condensation were deprotected under Zemplen conditions 9 
at 0 °C to give the final glycoclusters 2a and 2b in 81% and 82% yield respectively (Scheme 5).  10 
 1 
Scheme 5. Synthesis of 2a and 2b. 2 
 3 
2.2. Binding affinity measurements  4 
The ability of increasing concentrations (from 10-7 mg/mL to 1 mg/mL) of each new compound to inhibit the 5 
binding between the native 19F CPS, coated onto plates, and the mouse anti-19F polyclonal antibodies was 6 
evaluated in a classical competitive ELISA. Figure 3 shows the inhibition curves obtained with the 7 
compounds under evaluation.  8 
 9 
 10 
Figure 3. Results of the Elisa experiments. Concentration/response curves of tested compounds on the 11 
inhibition of the binding between SP19F native polysaccharide, coated onto the plates, and the anti-19F 12 
antibodies, evaluated by a competitive ELISA method. Values are means of at least four experiments run in 13 
triplicate 14 
 15 
The relative efficacy of each compound was assessed by determining its maximum effect of inhibition at 1 16 
mg/mL, while the concentration that produces the 50% of the possible maximum effect (IC50) was 17 
calculated when the curve reaches a plateau and taken as indirect index of the relative potency (Table 1). 18 
The activities of the new compounds were compared with those of the natural 19F polysaccharide and the 19 
19F trisaccharide repeating unit (SP19F-RU, see structure in SI) [38, 40] as the reference compound. The 20 
maximum inhibition observed for 19F CPS was fixed as the 100%. 21 
 22 
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Table 1: Results of the competitive Elisa assay 2 
 3 
Our results demonstrate that the spatial preorganization of the mannosamide units on the calixarene 4 
effectively increases their efficacy in a way that depends on the valency and on the tridimensional 5 
architecture of the macrocycle scaffold. In fact, comparing the maximum % of inhibition (Table 1) found for 6 
the monomeric model 1-MON (16%) with that of calixarene 1a (34%), also considering that the 7 
concentration of the ManAc epitope is substantially the same for the two compounds (2.1 and 2.2 mM for 8 
1-MON and 1a, respectively), the single mannosamide unit evidences an efficacy almost 2 fold higher when 9 
it is displaced on the calix[4]arene scaffold, which raises to 3 fold with the glycocalix[6]arene 1d. The 10 
efficacy of the tetravalent calixarenes 1a-c appears to be related to their conformational properties and the 11 
consequent geometry of presentation of the mannosamine units. In fact, the percentage of inhibition 12 
increases from the cone isomer to the 1,3-alternate and to the conformationally mobile (1b 10 ± 2 %, 1c 21 13 
± 3%, 1a 34 ± 7). This suggests that, despite the same number of saccharide units in these three ligands, the 14 
upper rim of ligand 1b is too crowded for an effective interaction with the antibodies resulting even worse 15 
than the monovalent model 1-MON. The better behavior of 1c supports this hypothesis since it exposes 16 
only two sugar units per part of the space with a reduced steric hindrance and perhaps an overall more 17 
convenient arrangement with respect to 1b. However, also this blocked display of 1c seems not to be the 18 
optimal one, as reflected in its lower level of efficacy with respect to the mobile isomer 1a that evidently 19 
can adapt itself for a better interaction with the antibodies as allows the epitope units to better adapt to 20 
the binding sites. Flexibility appears then to play an important role in determining the efficacy. The inability 21 
of compound calix[4]-Gal, a tetra thioureidoglycocalixarene based on the same calix[4]arene scaffold as 1a 22 
but bearing a non-related sugar (galactose), in inhibiting the binding between 19F CPS and anti-19F 23 
antibodies confirms the specificity of the sugar recognition and excludes an unspecific cross-reaction with 24 
the calixarene scaffold. On the whole, the conformational properties, the related geometry of exposition of 25 
the mannosamine units, the flexibility together with the higher valency could explain the highest efficacy 26 
(maximal inhibition 48 ± 8%) and potency (IC50= 9.5x10
-2 mg/mL) showed by glycocalix[6]arene 1d. 27 
Calix[6]arene was then selected as the more promising scaffold for the functionalization with the SP19F 28 
trisaccharide repeating unit analogs 2a and 2b. 29 
As shown in Figure 3 and reported in Table 1, glycocalix[6]arene 2a and 2b, decorated with six trisaccharide 30 
SP19F repeating units, significantly improve efficacy (75-78% of inhibition) and affinity (IC50= 1.9x10
-3 and 31 
8.6x10-4 mg/mL, respectively) towards the antibodies with respect to the simpler cluster 1d (48% of 32 
inhibition, IC50= 9.5x10
-2 mg/mL). This result can be explained considering the nature of the saccharide 33 
ligands on the two clusters: the trisaccharide repeating unit is a more specific epitope for the anti-19F 34 
antibodies, whereas the lower, but still non-negligible, activity of compound 1d could be ascribed to a 35 
predominant role of the mannosamine unit into the trisaccharide. Moreover, and more importantly, both 1 
glycocalixarenes 2a and 2b are more active than the single trisaccharide unit (52% of inhibition and IC50= 2 
2.1 x 10-2 mg/mL) showing once more and more significantly that the presentation of the epitope units on 3 
this type of scaffold increases the strength and the efficacy of antibody binding. In this framework, at the 4 
maximum of inhibition, the trisaccharide attached to the calix[6]arene platform is at a very similar 5 
concentration (1.31 mM) as when used alone (1.47 mM), but induces an efficacy 1.5 fold higher than 6 
SP19F-RU, determining an inhibition of the binding over 70% significantly higher than the 52% of the 7 
SP19F-RU. These data strongly suggest that the glycocalix[6]arene thanks to its peculiar conformational 8 
mobility enables a proper presentation of the trisaccharide repeating units that improves the strength of 9 
the ligand-receptor interactions well mimicking the conformational organization of the epitopes generated 10 
by the natural 19F polysaccharide and recognized by the specific antibodies. This result is even more 11 
significant if we consider that the chemical structure of calixarenes 2a and 2b is much simpler than the one 12 
of the natural polysaccharide and yet able to provide a significant inhibitory effect. As a consequence, the 13 
maximum of inhibition compared with that of 19F CPS is relevant, 75% of inhibition versus the 100%. 14 
Furthermore, the structural difference due to the α and β anomeric connection of the trisaccharide to the 15 
spacer has no significant influence on the efficacy of the two ligands 2a and 2b, although resulted in slightly 16 
different potencies. This means that, in perspective, the separation of the two anomers 15 and 15 could 17 
even be avoided, proceeding in the coupling as a mixture of both with the calixarene isothiocyanate. The 18 
statistic products containing randomly both anomers should substantially show the same biological activity 19 
as 2a and 2b with a not negligible save in the procedure of preparation. 20 
 21 
 22 
3. CONCLUSIONS 23 
Fully synthetic carbohydrate-based vaccines  offer the advantage to allow site-selective conjugation of 24 
saccharide epitopes [37, 41, 42] and to incorporate into the nanosystems active mediators to increase 25 
vaccine efficacy. The possibility to accurately control the number and type of vaccine active species ensures 26 
homogeneous composition, which is important to induce highly reproducible biological properties with a 27 
better safety profile. In this work, the calix[6]arene scaffold represents a valuable platform for the 28 
simultaneous presentation of multiple copies of minimized portions of the 19F CPS. In fact, this system, 29 
bearing six trisaccharide repeating units linked through a thiourea group to the macrocycle via an 30 
aminopropyl spacer, has been able to efficiently bind to anti-19F antibodies with a significant improvement 31 
of the inhibition activity compared to the one of the single repeating unit. The overall efficiency is very 32 
high, especially considering the low number of exposed saccharide antigens compared to the large number 33 
of repeating units that are present in the natural polymer. Evidently, the structural properties of the 34 
calixarene can properly present the exposed saccharide units in a tridimensional arrangement that is 35 
significantly similar to that of the natural epitopes in CPS. Our data clearly suggest that, in perspective, 36 
glycocalixarenes 2a and 2b, or even closely related systems with slightly longer saccharide fragments, could 37 
be functionalized with immunogenic peptides in order to elicit an antibacterial specific immune response. A 38 
structurally well-defined and easily reproducible multivalent glycocalixarene should avoid the use of 39 
complex oligosaccharide species, which are generally required for immunogenicity. Calixarenes seem then 40 
to have great potential as carriers for the development of fully synthetic carbohydrate-based vaccines, and 41 
this work contributes towards this direction. 42 
 43 
4. EXPERIMENTAL SECTION 44 
4.1. Chemical procedures 45 
General information. All moisture sensitive reactions were carried out under a nitrogen or argon 46 
atmosphere, using previously oven-dried glassware. All dry solvents were prepared according to standard 47 
procedures, distilled before use and stored over 3 or 4 Å molecular sieves. All other reagents were 48 
commercial samples and used without further purification. Analytical TLC were performed using prepared 49 
plates of silica gel (Merck 60 F-254 on aluminum) and then, according to the functional groups present on 50 
the molecules, revealed with UV light or using staining reagents: FeCl3 (1% in H2O/MeOH 1:1), H2SO4 (5% in 51 
EtOH), ninhydrin (5% in EtOH), basic solution of KMnO4 (0.75% in H2O), molybdic acid solution 1 
(molybdatophosphorus acid and Ce(IV)sulphate in 4% sulphuric acid). Reverse phase TLC were performed 2 
using silica gel 60 RP-18 F-254 on aluminium sheets. Merck silica gel 60 was used for flash chromatography 3 
(40-63 μm) and for preparative TLC plates (10-12 μm). Sigma Aldrich C18 reverse phase silica gel was used 4 
for flash chromatography. 1H NMR and 13C NMR spectra were recorded on Bruker AV300 and Bruker AV400 5 
spectrometers (observation of 1H nucleus at 300 MHz and 400 MHz, respectively, and of 13C nucleus at 75 6 
MHz and 100 MHz, respectively) and partially deuterated solvents were used as internal standards to 7 
calculate the chemical shifts (δ values in ppm). All 13C NMR spectra were performed with proton 8 
decoupling. For 1H NMR spectra recorded in D2O at temperatures higher that 25°C the correction of 9 
chemical shifts was performed using the expression δ = 5.060 - 0.0122×T(°C) + (2.11×10-5)×T2(°C) [43] to 10 
determine the resonance frequency of water protons. Electrospray ionization (ESI) mass analyses were 11 
performed with a Waters single-quadrupole spectrometer in positive or negative mode using MeOH or 12 
CH3CN as solvents or with a LTQ Orbitrap XL spectrometer in positive ionization mode. Melting points were 13 
determined on an Electrothermal apparatus in closed capillaries. Microwave reactions were performed 14 
using CEM Discovery System reactor. 15 
5,11,17,23-Tetraamino-25,26,27,28-tetramethoxy-calix[4]arene [25], 5,11,17,23-tetraamino-25,26,27,28-16 
tetrapropoxy-calix[4]arene cone [27], 5,11,17,23-tetraamino-25,26,27,28-tetrapropoxy-calix[4]arene 1,3-17 
alternate [25], 5,11,17,23,29,35-hexaamino-37,38,39,40,41,42-hexamethoxycalix[6]arene [26], 1-amino-4-18 
propoxy benzene [44], 5,11,17,23-tetraisohiocyanate-25,26,27,28-tetrapropoxy-calix[4]arene cone [28], N-19 
(benzyloxycarbonyl)aminopropyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-mannopyranoside [29] were 20 
prepared according to literature procedures.  21 
4.1.1. 5,11,17,23-Tetraisothiocyanate-25,26,27,28-tetramethoxy-calix[4]arene (4a): 22 
In a two-neck round-bottom flask 5,11,17,23-tetraamino-25,26,27,28-tetramethoxy-calix[4]arene 3a (0.82 23 
g, 1.22 mmol) was dissolved in 65 mL of dry toluene under N2 atmosphere. Then thiophosgene (1.11 mL, 24 
14.64 mmol, caution) and Et3N (4.07 mL, 29.28 mmol) were added and the mixture was allowed to react at 25 
room temperature for 48 h. The solvent was removed under reduced pressure and the crude was 26 
redissolved in dichloromethane. The organic phase was washed with water (2x70 mL), 1 N HCl (70 mL) and 27 
then with a saturated solution of NaCl (2x80 mL). The solvent was removed under reduced pressure and 28 
the residue purified by column chromatography (hexane/DCM 7/3, v/v) to afford a yellowish solid (0.19 g, 29 
0.28 mmol, 23% yield). Mp: dec > 180°C. 1H NMR (400 MHz, CDCl3) δ (ppm): 7.14 (s, 1.6H, ArH, partial 30 
cone), 7.02 (s, 1.6H, ArH, partial cone), 6.81 (s, 1.6H, ArH, partial cone), 6.65 (s, 1.6H, ArH, cone), 6.29 (s, 31 
1.6H, ArH, partial cone), 4.26 (d, J = 13.5 Hz, 0.8H, ArCHHaxAr, cone), 3.97 (d, J =14.0 Hz, 1.6H, ArCHHaxAr, 32 
partial cone), 3.78 (s, 2.4H, OCH3, cone), 3.74 (s, 2.4H, OCH3, partial cone), 3.68 (s, 4.8H, OCH3, partial cone), 33 
3.56 (s, 3.2H, ArCHHeqAr, partial cone), 3.13 (d, J = 13.5 Hz, 0.8H, ArCHHeqAr, cone), 3.06 (d, J = 14.0 Hz, 34 
1.6H, ArCHHeqAr, partial cone), 3.04 (s, 2.4H, OCH3, partial cone). 
13C NMR (100 MHz, CDCl3) δ (ppm): 156.9, 35 
156.4 (CAr ipso), 135.6, 134.3, 132.5, 127.7, 126.5, 126.2, 125.7, 125.6 (CAr, NCS), 61.9, 61.4, 60.2, 59.8 36 
(OCH3), 35.0 (ArCH2Ar, partial cone), 30.3, 30.1 (ArCH2Ar, cone and partial cone). HRMS (ESI-TOF) m/z: calcd 37 
for C36H28N4O4S4Na [(4a+Na)
+] 731.0886, found 731.0861. 38 
4.1.2. 5,11,17,23-Tetraisothiocyanate-25,26,27,28-tetrapropoxy-calix[4]arene 1,3-alternate (4c): 39 
In a two-neck round-bottom flask 5,11,17,23-tetraamino-25,26,27,28-tetrapropoxy-calix[4]arene 1,3-40 
alternate 3c (1.23 g, 1.96 mmol) was dissolved in 25 mL of dry toluene under N2 atmosphere. Then 41 
thiophosgene (1.8 mL, 23.47 mmol, caution) and Et3N (6.53 mL, 46.94 mmol) were added and the mixture 42 
was allowed to react at room temperature for 48 h. The solvent was removed under reduced pressure and 43 
the crude was redissolved in dichloromethane. The organic phase was washed twice with distilled H2O (30 44 
mL), once with 1 N HCl (30 mL) and then twice with a saturated solution of NaCl (40 mL). The solvent was 45 
removed under reduced pressure and the desired compound was obtained in 33% yield as an off-white 46 
solid after purification by column chromatography (cyclohexane/DCM 4/1 v/v) (0.53 g, 0.65 mmol). Mp: 47 
220-221 °C. 1H NMR (400 MHz, CDCl3) δ (ppm): 6.90 (s, 8H, ArH), 3.65 (t, J = 7.2 Hz, 8H, OCH2), 3.47 (s, 8H, 48 
ArCH2Ar), 1.87-1.78 (m, 8H, OCH2CH2CH3), 1.09 (t, J = 7.2 Hz, 12H, CH2CH3). 
13C NMR (100 MHz, CDCl3) δ 49 
(ppm): 155.3 (CAr ipso), 134.0 (NCS), 127.1 (CAr ortho), 125.0 (CAr para), 74.7 (OCH2), 35.1 (ArCH2Ar), 23.9 50 
(OCH2CH2CH3), 10.7 (CH2CH3). HRMS (ESI-TOF) m/z: calcd for C44H44N4O4S4Na [(4c+Na)
+] 843.2138, found 1 
843.2156. 2 
4.1.3. 5,11,17,23,29,35-Hexaisothiocyanate-37,38,39,40,41,42-hexamethoxy-calix[6]arene (4d): 3 
In a round-bottom flask 3d (0.15 g, 0.185 mmol) was dissolved in DCM (5 mL) under N2 atmosphere. Then 4 
thiophosgene (254 µL, 3.33 mmol, caution), BaCO3 (0.657 g, 3.33 mmol) and H2O (3 mL) were added with 5 
the remaining amount of DCM (5 mL). The mixture was was allowes to react at rt for 48 h and then diluted 6 
with DCM/H2O. The organic phase was separated from the aqueous layer and evaporated under reduced 7 
pressure. The crude thus obtained was purified by flash chromatography (hexane/EtOAc 8/2, v/v) and 8 
crystallized with CH3CN to yield the pure product as a white solid (39 mg, 0.037 mmol, 20%). Mp: dec > 9 
200°C. 1H NMR (300 MHz, CDCl3) δ (ppm): 6.74 (s, 12H, ArH), 3.89 (s, 12H, ArCH2Ar), 3.54 (s, 18H, OCH3). 
13C 10 
NMR (75 MHz, CDCl3) δ(ppm): 155.3 (CAr ipso), 135.2 (CAr ortho), 133.9 (NCS), 126.6 (CAr para), 126.2 (CAr 11 
meta), 61.0 (OCH3), 30.2 (ArCH2Ar). HRMS (ESI-TOF) m/z: calcd for C54H42N6O6S6Na [(4d+Na)
+] 1085.1388, 12 
found 1085.1414 (80%); calcd for C54H42N6O6S6K [(4d+K)
+] 1101.1127, found 1101.1151 (100%).  13 
4.1.4. Aminopropyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-mannopyranoside (7):  14 
To a solution of N-(Benzyloxycarbonyl)aminopropyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-15 
mannopyranoside (6) (0.54 g, 0.79 mmol) in a 4:1 mixture of AcOEt/EtOH (10 mL), Pd/C (10%) was added 16 
and the suspension was shaken in a Parr hydrogenator for 90 minutes under 1.5 bar of H2 at room 17 
temperature, after which the catalyst was filtered off and the filtrate evaporated under vacuum, to give the 18 
desired product as an orange oil (0.373 g, 0.68 mmol, 86%). 1H NMR (300 MHz, CDCl3) δ (ppm): 7.38-7.13 19 
(m, 15H, ArH), 6.20 (d, J = 9.9 Hz, 1H, NHAc), 4.90-4.79 (m, 3H, H2, 2CHHPh), 4.57 (d, J = 11.9 Hz, 1H, 20 
CHHPh), 4.52-4.42 (m, 4H, H1, 3CHHPh), 3.93-3.82 (m, 1H, OCHHCH2), 3.73 (br, 2H, H6a,b), 3.68-3.62 (m, 21 
2H, H4, H5), 3.61-3.51 (m, 1H, OCHHCH2), 3.46-3.38 (m, 1H, H3), 2.83-2.74 (m, 2H, CH2CH2NH2), 2.03 (s, 3H, 22 
CH3CO), 1.77-1.69 (m, 2H, CH2CH2CH2). 
13C NMR (75 MHz, CDCl3) δ (ppm): 171.9 (COCH3), 138.2, 137.9, 23 
137.7, 128.4, 128.33, 128.31, 127.9, 127.85, 127.8, 127.7 (CAr), 99.5 (C1), 79.8 (C5), 75.0 (C3), 74.8 (CH2Ph), 24 
74.1 (C4), 73.3 (CH2Ph), 71.1 (CH2Ph), 68.9 (C6), 67.6 (OCH2), 49.2 (C2), 38.5 (CH2NH2), 27.9 (CH2CH2CH2), 23.6 25 
(COCH3). ESI-MS m/z: calcd for C32H41N2O6 [(7+H)
+] 549.3, found 549.0.  26 
4.1.5. N-(Boc)aminopropyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-mannopyranoside (8): 27 
Aminopropyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-mannopyranoside (7) (0.34 g, 0.63 mmol) was 28 
dissolved in MeOH (8 mL), then Et3N (348 μl, 2.5 mmol) and Boc2O (0.68 g, 3.13 mmol) were subsequently 29 
added. The reaction was allowed to react for 2 h, then the solvent was removed under vacuum. The pure 30 
product was obtained as a pale oil in quantitative yield (0.40 g, 0.61 mmol). 1H NMR (300 MHz, CDCl3) δ 31 
(ppm): 7.26-7.03 (m, 15H, ArH), 6.18 (d, J = 9.4 Hz, 1H, NHAc), 5.26 (br, 1H, NHBoc), 4.78-4.68 (m, 3H, H2, 32 
2CHHPh), 4.44 (d, J = 12.0 Hz, 1H, CHHPh), 4.40-4.31 (m, 4H, 3CHHPh, H1), 3.75-3.66 (m, 1H, OCHHCH2), 33 
3.64-3.58 (m, 2H, H6a,b), 3.56-3.51 (m, 2H, H4, H5), 3.50-3.39 (m, 1H, OCHHCH2), 3.37-3.29 (m, 1H, H3), 3.11-34 
3.05 (m, 2H, CH2CH2NHBoc), 1.89 (s, 3H, COCH3), 1.66-1.54 (m, 2H, CH2CH2CH2), 1.31 (s, 9H, C(CH3)3). 
13C 35 
NMR (100 MHz, CDCl3) δ (ppm): 170.8 (COCH3), 156.1 (CO(CH3)3), 146.7, 138.2, 137.9, 137.8, 128.4, 128.3, 36 
128.2, 127.8, 127.78, 127.73, 127.6 (CAr), 99.5 (C1), 85.0 (C(CH3), 80.3 (C5), 74.9 (C3), 74.7 (CH2Ph), 74.0 (C4), 37 
73.3 (CH2Ph), 71.0 (CH2Ph), 68.8 (C6), 67.1 (OCH2), 49.2 (C2), 37.6 (CH2NH2), 29.7 (CH2CH2CH2), 27.2 (C(CH3)3), 38 
23.3 (COCH3). ESI-MS m/z: calcd for C37H48N2O8Na [(8+Na)
+] 671.3, found 671.1.  39 
4.1.6. N-(Boc)aminopropyl 2-acetamido-2-deoxy-β-D-mannopyranoside (9): 40 
In a MW sealed vessel N-(Boc)aminopropyl 2-acetamido-3,4,6-tri-O-benzyl-2-deoxy-β-D-mannopyranoside 41 
(8) (0.60 g, 0.93 mmol) was dissolved in a MeOH/H2O mixture  (5 mL, 1/1 v/v) and Pd/C (10%) in catalytic 42 
amount and then NH4COOH (0.23 g, 3.7 mmol) were added. The mixture was heated at 60 °C under 43 
microwave irradiation (150 W) for 1.5 h. The catalyst was filtered off and the solvent removed under 44 
reduced pressure, to give the desired product as white foam (0.30 g, 0.79 mmol, 85%) 1H NMR (400 MHz, 45 
MeOD) δ (ppm): 4.65 (s, 1H, H1), 4.47 (d, J = 3.2 Hz, 1H, H2), 3.87 (br, 3H, H6a,b, OCHHCH2), 3.68 (dd, J3,2 = 46 
4.0, J3,4 = 9.5 Hz, 1H, H3), 3.63-3.57 (m, 1H, OCHHCH2), 3.53 (t, J = 9.5 Hz, 1H, H4), 3.31-3.25 (m, 1H, H5), 3.13 47 
(t, J = 6.4 Hz, 2H, CH2CH2NHBoc), 2.05 (s, 3H, COCH3), 1.73 (t, J = 6.0 Hz, 2H, CH2CH2CH2), 1.45 (s, 9H, 48 
C(CH3)3). 
13C NMR (100 MHz, MeOD) δ (ppm): 173.4 (COCH3), 157.1 (CO(CH3)3), 99.4 (C1), 78.5 (C(CH3)3), 76.9 49 
(C5), 73.0 (C3), 66.9 (C4), 66.3 (OCH2), 60.5 (C6), 53.5 (C2), 36.9 (CH2NH2), 29.5 (CH2CH2CH2), 27.4 (C(CH3)3), 1 
21.4 (COCH3). ESI-MS m/z: calcd for C16H32N2O8Na [(9+Na)
+] 401.2, found 401.3.  2 
4.1.7. N-(Boc)aminopropyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopyranoside (10): 3 
N-(Boc)aminopropyl 2-acetamido-2-deoxy-β-D-mannopyranoside (9) (0.18 g, 0.47 mmol) was dissolved in 4 
pyridine (6 mL) and then acetic anhydride was added (740 μl, 7.91 mmol). The reaction mixture was stirred 5 
at room temperature for 1 h, then the solvent removed under reduced pressure. The pure compound was 6 
obtained after purification via flash column chromatography (EtOAc/hexane 4/1, v/v) as a white foam in 7 
quantitative yield (0.23 g, 0.46 mmol). 1H NMR (300 MHz, CDCl3) δ (ppm): 5.94 (br, 1H, NHAc), 5.06 (t, J = 8 
9.2 Hz, 1H, H4), 4.97 (dd, J3,2 = 4.0, J3,4 = 9.2 Hz, 1H, H3), 4.67-4.60 (m, 3H, H1, H2, NHBoc), 4.27 (dd, J6a,5 = 6.0, 9 
J6a,6b = 15.0 Hz, 1H, H6a), 4.12 (dd, J6b,5 = 6.0, J6b,6a = 15.0 Hz, 1H, H6b), 3.90-3.83 (m, 1H, OCHHCH2), 3.68-3.58 10 
(m, 1H, H5), 3.55 (br, 1H, OCHHCH2), 3.22-3.15 (m, 2H, CH2CH2NHBoc), 2.09 (s, 3H, CH3CO), 2.06 (s, 3H, 11 
CH3CO), 2.04 (s, 3H, CH3CO), 2.00 (s, 3H, NHCOCH3), 1.77-1.68 (m, 2H, CH2CH2CH2), 1.42 (s, 9H, C(CH3)3). 
13C 12 
NMR (75 MHz, CDCl3) δ (ppm): 171.4, 170.5, 170.2, 169.7 (COCH3), 156.1 (CO(CH3)3), 98.7 (C1), 78.9 (C(CH3), 13 
72.2 (C5), 71.4 (C3), 67.0 (OCH2), 66.2 (C4), 62.6 (C6), 49.9 (C2), 37.3 (CH2NH2), 29.5 (CH2CH2CH2), 28.3 14 
(C(CH3)3), 22.9, 20.6, 20.5 (COCH3). ESI-MS m/z: calcd for C22H36N2O11Na [(22+Na)
+] 527.2, found 527.4.   15 
4.1.8. Aminopropyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopyranoside (11): 16 
N-(Boc)aminopropyl 2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopyranoside (10) (0.24 g, 0.47 mmol) 17 
was dissolved in dry DCM (15 mL), then trifluoroacetic acid (1.27 mL, 16.45 mmol) was added dropwise. 18 
The reaction was allowed to stir at room temperature for 1 h, then it was quenched by the addition of Et3N. 19 
The solvent was evaporated under reduced pressure and the desired compound was obtained as a yellow-20 
orange oil in quantitative yield (0.19 g, 0.46 mmol). 1H NMR (300 MHz, CDCl3) δ (ppm): 6.85 (d, J = 9.0 Hz, 21 
1H, NHAc), 5.08 (t, J = 9.6 Hz, 1H, H4), 4.99 (dd, J3,2 = 4.6, J3,4 = 9.6 Hz, 1H, H3), 4.78-4.70 (m, 2H, H1, H2), 4.24 22 
(dd, J6a,5 = 6.0, J6a,6b = 12.4 Hz, 1H, H6a), 4.13 (dd, J6b,5 = 2.4, J6b,6a = 12.0 Hz, 1H, H6b), 4.01-3.92 (m, 1H, 23 
OCHHCH2), 3.81-3.74 (m, 2H, H5, OCHHCH2), 3.71-3.64 (m, 2H, CH2CH2NH2), 2.07 (s, 3H, CH3CO), 2.02 (s, 6H, 24 
CH3CO), 1.99 (s, 3H, NHCOCH3), 2.00-1.96 (m, 2H, CH2CH2CH2). 
13C NMR (100 MHz, CDCl3) δ (ppm): 161.5, 25 
161.2, 160.4 (COCH3), 98.2 (C1), 72.3 (C5), 71.3 (C3), 66.6 (OCH2), 66.0 (C4), 62.4 (C6), 49.5 (C2), 37.4 (CH2NH2), 26 
26.3 (CH2CH2CH2), 22.4, 20.4 (COCH3). HRMS (ESI-TOF) m/z: calcd for C17H28N2O9Na [(11+Na)
+] 427.1687, 27 
found 427.1658.  28 
4.1.9. N-(tertbutoxycarbonyl)-3-amminopropyl (2-acetamido-3,4,6-tri-O-acetyl-2-deoxy--D-29 
mannopyranosyl)-(14)-(2,3,6-tri-O-acetyl--D-glucopyranosyl)-(12)-3,4-di-O-acetyl-L-30 
rhamnopyranoside (15): Compound 16 [37] (0.19 g, 0.147 mmol) and N-(benzyloxycarbonyl)-3-31 
amminopropyl (0.12 g, 0.586 mmol), as previously described [38], were dissolved in dry CH2Cl2 (3 ml) and 32 
activated powder molecular sieves 4 Å (0.10 g) were added. The suspension was stirred under Ar 33 
atmosphere at room temperature for 15 minutes, then it was cooled to 0 °C and TMSOTf 0.1 M in dry 34 
CH2Cl2 (0.29 ml, 0.029 mmol) was added. After 15 minutes, the reaction was quenched by the addition of 35 
TEA, filtered over a Celite pad and the solvent evaporated under reduced pressure. Purification of the crude 36 
through flash chromatography (Hexane/Ethyl Acetate 6:4) afforded 0.48 g of the less polar -anomer, 0.80 37 
g of a mixture of the two anomers, and 0.63 g of the -anomer (17 overall yield: 96%). 17 and 17 were 38 
reacted separately in the next step. To a solution under Argon of compound SP3 in MeOH (0.01M), Boc2O 39 
(3.5 eq.) and then Pd(OH)2/C (1:1, w/wsubstrate) were added. The mixture was stirred under hydrogen 40 
atmosphere for 3 h, and checked by TLC (E/A, 1:1) to confirm that the Z-amino protecting group has been 41 
exchanged with BOC. Then, one drop of HCl 1N was added, and the reaction was stirred again under 42 
hydrogen atmosphere overnight. TLC (DCM/MeOH, 75:25) control showed that the reaction was 43 
completed, then few drops of dry Py were added, and the reaction was filtered over filter paper. After 44 
evaporation of the solvent, the crude was dissolved in dry Py (0.03M), and acetic anhydride was added 45 
(Ac2O/Py, 1:2) together with a catalytic amount of DMAP. The reaction was stirred at room temperature for 46 
19 h, diluted with MeOH, and then the solvent evaporated. Purification of the crude by flash 47 
chromatography (hexane/EtOAc, 1:9) gave compound 15 as an amorphous white solid. 48 
15: 0.32 g of 15 were obtained starting from 0.48 g of 17 (88% yield). D
20 = +22.3 (c = 1 in 1 
chloroform). 1H-NMR (CDCl3):  = 5.90 (d, 1H, J2’,NH = 7.2 Hz, NH), 5.39 (t, 1H, J2’,3’ = J3’,4’ = 9.4 Hz, H-3’), 2 
5.29-5.20 (m, 2H, H-1’, 3), 5.15-5.03 (m, 2H, H-4, 4’), 4.92 (dd, 1H, J2’’,3’’ = 3.8 Hz, J3’’,4’’ = 10.0 Hz, H-3’’), 3 
4.76-4.56 (m, 5H, H-1, 1’’, 2’, 2" and NH), 4.36 (dd, 1H, J5’’,6a’’ = 5.3 Hz, J6a’’,6b’’ = 12.5 Hz, H-6a’’), 4.30-4 
4.22 (m, 2H, 2 H-6’), 4.15-4.03 (m, 2H, H-5’, 6a’’), 4.02-3.98 (m, 1H, H-2), 3.84-3.69 (m, 3H, H-a, 4’, 5), 5 
3.67-3.59 (m, 1H, H-5’’), 3.49-3.40 (m, 1H, H-a’), 3.28-3.17 (m, 2H, 2 H-c), 2.21-1.98 (9 s, 27H, 9 CH3), 6 
1.85-1.75 (m, 2H, 2 H-b), 1.46 (s ,9H, (CH3)3CO), 1.20 (d, 3H, J5,6 = 6.0 Hz ,3 H-6). 
13C-NMR (CDCl3):  = 7 
171.9-169.6 (9C, C=O), 155.9 (C=O), 98.2 (C-1’’), 96.4 (C-1), 93.3 (C-1’), 75.5 (C-4’), 73.7 (C-2), 72.7 (C-8 
5’’), 71.9 (C-3’’). 71.3 (C-4), 71.0 (C-2’), 70.7 (C-3’), 69.9 (C-3), 68.2 (C-5’), 66.6 (C-5), 65.9 (C-a), 65.7 9 
(C-4’’), 62.2 (C-6’’), 62.0 (C-6’), 50.8 (C-2’’), 37.83 (C-c), 31.6 (Me3C), 29.8 (C-b), 28.4 (Me3C), 21.2-20.6 10 
(9C, CH3CO ), 17.7 (C-6). MS (ESI) m/z (): 1045.3 (100) [M+Na]
+. 11 
15: 0.42 g of 15 were obtained starting from 0.63 g of 17 (85% yield). []D
20 = +55.4 (c = 1 in 12 
chloroform). 1H-NMR (CDCl3):  = 5.94 (d, 1H, J2’,NH = 7.2 Hz, NH), 5.62 (br d, 1H, J1’,2’ = 3.9 Hz, H-1’), 13 
5.41 (t, 1H, J2’,3’ = J3’,4’ = 9.5 Hz, H-3’), 5.13-5.04 (m, 2H, H-4, 4’’), 4.98 (dd, 1H, J2,3 = 3.0 Hz, J3,4 = 10.0 14 
Hz, H-3), 4.92 (dd, 1H, J2’’,3’’ = 4.0 Hz, J3’’,4’’ = 10.0 Hz, H-3’’), 4.75 (dd, 1H, J1’,2’ = 3.9 Hz, J2’,3’ = 10.2 Hz, 15 
H-2’), 4.69 (br s, 1H, H-1’’), 4.63-4.58 (m, 1H, H-2"), 4.47 (s, 1H, H-1), 4.36 (dd, 1H, J5’’,6a’’ = 5.4 Hz, 16 
J6a’’,6b’’ = 12.4 Hz, H-6a’’), 4.25 (dd, 1H, J5’,6a’ = 5.0 Hz, J6a’,6b’ = 11.8 Hz, H-6a’), 4.21-4.12 (m, 3H, H-2, 5’, 17 
6b’), 4.06 (dd, 1H, J5’’,6a’’ = 2.2 Hz, J6a’’,6b’’ = 12.4 Hz, H-6a’’), 3.87-3.79 (m, 1H, H-a), 3.69 (t, 1H, J3’,4’ = 18 
J4’,5’ = 9.5 Hz, H-4’), 3.65-3.61 (m, 1H, H-5’’), 3.50-3.41 (m, 2H, H-a, 5), 3.29-3.19 (m, 1H, H-c), 3.11-19 
3.02 (m, 1H, H-c), 2.17-2.00 (9 s, 27H, 9 CH3), 1.82-1.66 (m, 2H, 2 H-b), 1.45 (s ,9H, (CH3)3CO), 1.26 (d, 20 
3H, J5,6 = 6.0 Hz ,3 H-6). 
13C-NMR (CDCl3):  = 172.1-169.5 (9C, C=O), 156.1 (C=O), 100.9 (C-1), 98.2 (C-21 
1’’), 94.3 (C-1’), 75.7 (C-4’), 72.7 (C-5’’), 72.3 (C-2), 71.9 (2C, C-3, 3’’). 71.1 (C-4), 70.7 (C-5), 70.5 (C-22 
3’), 70.3 (C-2’), 67.8 (C-5’), 67.6 (C-a), 65.8 (C-4’’), 62.2 (2C, C-6, 6’’), 50.8 (C-2’’), 37.3 (C-c), 31.6 23 
(Me3C), 29.4 (C-b), 28.4 (Me3C), 23.1-20.6 (9C, CH3CO ), 17.7 (C-6). MS (ESI) m/z (): 1045.3 (100) 24 
[M+Na]+. 25 
4.1.10. 5,11,17,23-Tetrakis-N-[3-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopiranosyloxy)-26 
propyl-thioureido]-25,26,27,28-tetrapropoxycalix[4]arene Cone (5b): 27 
In a two-neck round-bottom flask calixarene 4b (0.05 g, 0.0609 mmol) was dissolved in dry DCM (6 mL) 28 
under N2 atmosphere, then sugar 11 (0.123 g, 0.305 mmol) and Et3N (255 μL, 1.83 mmol) were added. The 29 
mixture was stirred at rt for 24 h, after which half equivalents of sugar and Et3N were added and the 30 
mixture stirred for additional 16 h. The solvent was removed under reduced pressure and the crude was 31 
purified via flash column chromatography (DCM/MeOH 20/1, v/v) yieldig cone derivative 5b in 37% yield as 32 
a white solid (0.0547 g, 0.0225 mmol). Mp: dec > 130 °C. 1H NMR (300 MHz, CDCl3) δ (ppm): 8.36 (br, 4H, 33 
NHCS), 6.65 (br, 8H, ArH), 6.38 (br, 8H, CSNHCH2, NHAc), 5.15-5.09 (m, 8H, H3, H4), 4.78-4.74 (m, 8H, H2, H1), 34 
4.41 (d, J = 13.2 Hz, 4H, ArCHHaxAr), 4.27 (dd, J6a,5 = 5.6, J6a,6b = 12.0 Hz, 4H, H6a), 4.13 (dd, J6b,5 = 2.4, J6b,6a = 35 
12.0 Hz, 4H, H6b), 3.97-3.96 (m, 4H, OCHHCH2CH2), 3.84 (br, 12H, OCH2CH2CH3, CHHNHCS), 3.70-3.69 (m, 4H, 36 
H5), 3.57 (br s, 4H, OCHHCH2CH2), 3.49-3.48 (m, 4H, CHHNHCS), 3.14 (d, J = 13.2 Hz, 4H, ArCHHeqAr), 2.07 (s, 37 
12H, CH3CO), 2.05 (s, 12H, CH3CO), 2.03 (s, 12H, CH3CO), 2.01 (s, 12H, CH3CO), 1.96-1.90 (m, 16H, 38 
OCH2CH2CH3, CH2CH2CH2), 0.94 (t, J = 7.5 Hz, 12H, CH2CH3). 
13C NMR (75 MHz, CDCl3) δ (ppm): 180.4 (CS), 39 
172.1 (NHCOCH3), 170.7 (COCH3), 170.5 (COCH3), 169.8 (COCH3), 154.5 (CAr ipso), 136.2 (CAr ortho), 132.1 40 
(CAr para), 124.8 (CAr meta), 99.1 (C1), 77.3 (OCH2CH2CH3) 72.4 (C5), 71.4 (C4), 68.7 (OCH2CH2CH2), 66.0 (C3), 41 
62.5 (C6), 50.3 (C2), 43.0 (CH2NHCS), 30.9 (ArCH2Ar), 29.9 (CH2CH2CH2), 28.9 (OCH2CH2CH3), 23.4 (COCH3), 42 
23.2 (COCH3), 20.8 (COCH3), 20.7 (COCH3), 10.2 (CH2CH2CH3). HRMS (ESI-TOF) m/z: calcd for 43 
C112H156N12O40S4Na [(5b+2Na)
2+] 1241.4590, found 1241.4586.   44 
4.1.11. 5,11,17,23,29,35-Hexakis-N-[3-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopiranosyloxy)-45 
propyl-thioureido]-37,38,39,40,41,42-hexamethoxycalix[6]arene (5d): 46 
To a solution of compound 4d (0.0416 g, 0.0392 mmol) in DCM (8 mL) sugar 11 (0.111 g, 0.274 mmol) and 47 
NEt3 (273 μL, 1.96 mmol) were added and the mixture stirred at rt for 72 h. The solvent was removed under 48 
reduced pressure and the crude purified via flash column chromatography and preparative TLC 49 
(DCM/MeOH 94/6, v/v) to afford 5d as a yellowish solid (0.0317 mg, 0.0091 mmol, 23%). 1H NMR (400 50 
MHz, CDCl3) δ (ppm): 8.66 (br, 6H, NHCS), 6.92 (br, 12H, ArH), 6.57 (s, 12H, CSNHCH2, NHAc), 5.18 (br, 6H, 51 
H4), 5.03 (br, 6H, H3), 4.77 (br, 6H, H2), 4.71 (br, 6H, H1), 4.29 (br, 6H, H6a), 4.14 (br, 6H, H6b), 4.03-3.17 1 
(overlapped, 60H, OCHHCH2CH2, CHHNHCS, H5, ArCH2Ar, OCH3), 2.10 (s, 18H, CH3CO), 2.07 (s, 36H, CH3CO), 2 
2.03 (s, 18H, CH3CO), 1.81 (br, 12H, CH2CH2CH2). 
13C NMR (100 MHz, CDCl3) δ (ppm): 180.6 (CS), 172.1 3 
(COCH3), 170.7 (COCH3), 170.3 (COCH3), 169.7 (COCH3), 154.2 (CAr ipso), 134.8 (br, CAr ortho, CAr para), 125.3 4 
(CAr meta), 99.9 (C1), 72.5 (C5), 71.3 (C3), 68.6 (OCH2CH2CH2), 66.1 (C4), 62.6 (C6), 61.0 (OCH3), 50.4 (C2), 42.9 5 
(CH2NHCS), 29.7 (ArCH2Ar), 29.0 (CH2CH2CH2), 23.4 (NHCOCH3), 20.9 (COCH3), 20.8 (COCH3), 20.7 (COCH3). 6 
HRMS (ESI-TOF) m/z: calcd for C156H210N18O60S6Na2 [(5d+2Na)
2+] 1766.6028, found 1766.6047.   7 
4.1.12. N-[3-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopiranosyloxy)-propyl-thioureido]-4-8 
propoxy benzene (14): 9 
To a solution of 13 (0.03 g, 0.155 mmol) in dry DCM (4 mL) under N2 atmosphere, sugar 11 (0.0943 g, 0.233 10 
mmol) and NEt3 (324 μL, 2.33 mmol) were added and the mixture stirred for 12 h at rt. The solvent was 11 
removed under reduced pressure and the crude purified by flash column chromatography (DCM/MeOH 12 
20/1, v/v) yielding 14 as an off-white solid (0.0490 g, 0.0821 mmol, 53%). Mp: 90-91 °C. 
1
H NMR (400 MHz, 13 
CDCl3) δ (ppm): 8.25 (br, 1H, NHCS), 7.18 (d, J = 8.0 Hz, 2H, ArH), 6.86 (d, J = 8.0 Hz, 2H, ArH), 6.23 (br, 1H, 14 
CH2NHCS), 6.05 (d, J = 7.6 Hz, 1H, NHAc), 5.08 (t, J = 9.6 Hz, 1H, H4), 4.99 (dd, J3,2 = 4.0 Hz, J3,4 = 10.0 Hz, 1H, 15 
H3), 4.72 (d, J = 4.0 Hz, 1H, H2), 4.63 (s, 1H, H1), 4.26 (dd, J6a,5 = 5.2 Hz, J6a,6b = 12.4 Hz, 1H, H6a), 4.08 (d, J = 16 
12.0 Hz, 1H, H6b), 3.89-3.86 (m, 3H, OCHHCH2CH2, OCH2CH2CH3), 3.76 (br, 1H, CHHNHCS), 3.67-3.56 (m, 2H, 17 
H5, OCHHCH2CH2), 3.53 (br, 1H, CHHNHCS), 2.06 (s, 3H, COCH3), 2.03 (s, 3H, COCH3), 2.02(s, 3H, COCH3), 18 
1.97 (s, 3H, COCH3), 1.75 (m, 4H, OCH2CH2CH3, CH2CH2CH2), 0.98 (t, J = 7.2 Hz, 3H, CH2CH3). 
13C NMR (100 19 
MHz, CDCl3) δ (ppm):  181.7 (CS), 171.7 (NHCOCH3), 170.6 (COCH3), 170.1 (COCH3), 169.7 (COCH3), 157.9 20 
(CAr ipso), 129.8 (CAr ortho), 127.3 (CAr para), 127.3, 125.6 (CAr meta), 99.1 (C1), 72.5 (C5), 71.0 (C3), 69.8 21 
(OCH2CH2CH3), 68.5 (OCH2CH2CH2), 66.0 (C4), 62.4 (C6), 50.3 (C2), 43.1 (CH2NHCS), 29.7 (CH2CH2CH2), 23.4 22 
(COCH3), 20.8 (OCH2CH2CH3), 20.8, 20.7 (COCH3), 10.5 (OCH2CH2CH3). HRMS (ESI-TOF) m/z: calcd for 23 
C27H39N3O10SNa [(14+Na)
+] 620.2254, found 620.2261. 24 
4.1.13. 5,11,17,23,29,35-Hexakis-N-[3-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopyranosyl-25 
(14)-2,3,6-tri-O-acetyl-α-D-glucopyranosyl-(12)-3,4-di-O-acetyl-α-L-rhamnopyranosyloxy)-propyl-26 
thioureido]-37,38,39,40,41,42-hexamethoxycalix[6]arene (18a): 27 
15 (22 mg, 0.0215 mmol) was dissolved in dry DCM (4 mL) under Ar atmosphere. The temperature was 28 
decreased to 0 °C and 0.5 mL of trifluoroacetic were added. The reaction proceeded at room temperature 29 
for 1 hour, after which the TLC showed the complete consumption of the reagent, thus the solvent was 30 
evaporated at reduced pressure. The obtained deprotected product was dissolved in dry DCM (2 mL) and 31 
5,11,17,23,29,35-hexaisothiocyanate-37,38,39,40,41,42-hexamethoxy-calix[6]arene (4d) (2.5 mg, 0.00239 32 
mmol) and NEt3 (17 μL, 0.120 mmol) were added under Ar atmopshere. The mixture was stirred for 48 33 
hours at room temperature, after which the reaction was quenched by removal of the solvent at reduced 34 
pressure. The desired product was obtained after column chromatography (DCM/MeOH 96:4 v/v) as a 35 
white solid in 86% yield (13.5 mg, 0.00205 mmol). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.01 (br, 12H, ArH), 36 
5.91 (br, 6H, NHAc), 5.38 (t, J3’,4’ = J3’,2’ = 9.5 Hz, 6H, H3’), 5.24 (br, 12H, H3, H1’), 5.14-5.03 (m, 12H, H4, H4’), 37 
4.93 (br, 6H, H3’’), 4.77-4.67 (m, 12H, H2’, H1’’), 4.62 (br, 12H, H2’’, H1), 4.37 (dd, J6a,5 = 5.1, J6a,6b = 12.5 Hz, 6H, 38 
H6a’’), 4.25 (br, 12H, H6’), 4.12-4.03 (m, 12H, H5’, H6’’), 4.00 (br, 6H, H2), 3.84-3.70 (m, 18H, H5, H4’, 39 
OCHHCH2CH2), 3.67 (br, 12H, H5’’, OCHHCH2CH2), 3.45 (br, 12H, CH2NHCS), 2.16 (s, 18H, CH3CO), 2.13 (s, 40 
18H, CH3CO), 2.12 (s, 18H, CH3CO), 2.11 (s, 18H, CH3CO), 2.09 (s, 18H, CH3CO), 2.06 (s, 36H, CH3CO), 2.04 (s, 41 
18H, CH3CO), 2.02 (s, 18H, CH3CO), 1.88 (br, 12H, CH2CH2CH2), 1.19 (d, J = 5.8 Hz, 18H, H6). HRMS (ESI-TOF) 42 
m/z: calcd for C288H390N18O144S6Na4 [(6a+4Na)
4+] 1672.0388, found 1672.0396. 43 
4.1.14. 5,11,17,23,29,35-Hexakis-N-[3-(2-acetamido-3,4,6-tri-O-acetyl-2-deoxy-β-D-mannopyranosyl-44 
(14)-2,3,6-tri-O-acetyl-α-D-glucopyranosyl-(12)-3,4-di-O-acetyl-β-L-rhamnopyranosyloxy)-propyl-45 
thioureido]-37,38,39,40,41,42-hexamethoxycalix[6]arene (6b): 46 
15 (29 mg, 0.0283 mmol) was dissolved in dry DCM (4 mL) under Ar atmosphere. The temperature was 47 
decreased to 0 °C and 0.5 mL of trifluoroacetic were added dropwise. The reaction proceeded at room 48 
temperature for 1 hour, after which the TLC showed the complete consumption of the reagent, thus the 49 
solvent was evaporated at reduced pressure. The crude was then dissolved in dry DCM (3 mL) and 50 
5,11,17,23,29,35-hexaisothiocyanate-37,38,39,40,41,42-hexamethoxy-calix[6]arene (4d) (3.3 mg, 0.00314 1 
mmol) and NEt3 (21 μL, 0.157 mmol) were added under Ar atmopshere. The mixture was stirred for 48 2 
hours at room temperature, after which the reaction was quenched by removal of the solvent at reduced 3 
pressure. The desired product was obtained after column chromatography (DCM/MeOH 95/5, v/v) as a 4 
white solid in 82% yield (17 mg, 0.00258 mmol). 1H NMR (400 MHz, CDCl3) δ (ppm): 7.11 (br, 12H, ArH), 5 
5.93 (d, J = 7.3 Hz, 6H, NHAc), 5.60 (br, 6H, H1’), 5.41 (t, J = 9.1 Hz, 6H, H3’) 5.17-5.02 (m, 12H, H4’’, H4),  4.96 6 
(dd, J3,2 = 3.0, J3,4 = 10.1 Hz, 6H, H3), 4.93 (dd, J3’’,2’’ = 5.8, J3’’,4’’ = 9.9 Hz, 6H, H3’’) 4.74 (br, 6H, H1’’), 4.69 (br, 7 
6H, H2’), 4.62 (br, 6H, H2’’), 4.50 (br, 6H, H1), 4.39 (dd, 6H, H6a’’) 4.28 (br, 6H, H6a’), 4.13 (br, 18H, H2, H5’, H6b’), 8 
4.05 (d, J = 12.0 Hz, 6H, H6b’’), 3.86 (br, 12H, CH2NHCS), 3.75 (br, 6H, H4’), 3.66 (br, 6H, H5’’), 3.45 (br, 18H, H5, 9 
OCH2) 2.16 (s, 18H, CH3CO), 2.12 (s, 36H, CH3CO), 2.11 (s, 18H, CH3CO), 2.061 (s, 18H, CH3CO), 2.056 (s, 18H, 10 
CH3CO), 2.05 (s, 18H, CH3CO), 2.03 (s, 18H, CH3CO), 2.01 (s, 18H, CH3CO), 1.75 (br, 12H, CH2CH2CH2), 1.23 (d, 11 
J = 5.8 Hz, 18H, H6). 
13C NMR (100 MHz, CDCl3) δ (ppm): 172.1, 170.6, 170.5, 170.4, 170.1, 169.7, 169.6, 12 
135.2, 125.0, 100.8, 98.3, 94.0, 75.8, 72.6, 72.3, 71.9, 71.8, 71.0, 70.7, 70.4, 67.8, 65.6, 62.3, 62.1, 60.8, 13 
50.8, 41.8, 32.2, 29.7, 26.4, 23.4, 23.2, 21.3, 20.9, 20.8, 20.76, 20.68, 17.7, 14.1. HRMS (ESI-TOF) m/z: calcd 14 
for C288H390N18O144S6Na4 [(6b+4Na)
4+] 1672.0388, found 1672.0399. 15 
4.1.15. General procedure for the deacetylation reaction of glycocalix[n]arenes 5a-d and monomer 14: 16 
To a solution of the peracetylated compound in MeOH at 0 °C, freshly prepared MeONa was added till pH 17 
9. The solution was stirred for 3 hours, after which Amberlite IR-120 (H+), and 1 mL of H2O in the case of the 18 
hexacalixarenes, were added and the mixture stirred at rt till neutral pH. The resin was filtered off and the 19 
solvent removed under reduced pressure. 20 
4.1.15.1. 5,11,17,23-Tetrakis-N-[3-(2-acetamido-2-deoxy-β-D-mannopiranosyloxy)-propyl-thioureido]-21 
25,26,27,28-tetramethoxycalix[4]arene (1a): 22 
The crude was first purified by C18 reverse phase column chromatography (MeOH/H2O 5.5/4.5, v/v),and 23 
then by size exclusion chromatography on Sephadex G-25 as stationary phase (MeOH/H2O 1.5/8.5, v/v). 24 
The final purification step was performed via standard flash chromatography (i-PrOH/H2O/Et3N 8/2/0.5, 25 
v/v/v) to afford the mobile calix[4]arene 1a in 40% yield (0.037 g, 0.0191 mmol). Mp: dec > 140 °C. 1H NMR 26 
(400 MHz, D2O, 80 °C) δ (ppm): 6.98 (br, 8H, ArH), 4.69 (br, 4H, H1), 4.43 (br, 4H, H2), 3.88-3.22 (m, 48H, H3, 27 
H4, H5, H6a, H6b, OCH2CH2, CH2NHCS, OCH3), 1.97 (s, 12H, NHCOCH3), 1.80-1.74 (m, 8H, CH2CH2CH2). 
13C NMR 28 
(100 MHz, MeOD, 55 °C) δ (ppm): 180.6 (CS), 173.6 (NHCOCH3), 155.7 (CAr ipso), 135.32 (CAr ortho), 132.4 29 
(CAr para), 124.4 (CAr), 99.5 (C1), 77.0 (C5), 73.0 (C3), 67.2 (C4, OCH2CH2CH2), 61.0 (C6, OCH3), 53.6 (C2), 42.1 30 
(CH2NHCS, ArCH2Ar), 29.2 (CH2CH2CH2), 22.2 (NHCOCH3). HRMS (ESI-TOF) m/z: calcd for C80H116N12O28S4Na 31 
[(1a+Na)+] 1843.6803, found 1843.6812.  32 
4.1.15.2. 5,11,17,23-Tetrakis-N-[3-(2-acetamido-2-deoxy-β-D-mannopiranosyloxy)-propyl-thioureido]-33 
25,26,27,28-tetrapropoxycalix[4]arene Cone (1b): 34 
The pure product 1b was obtained after purification by C18 reverse phase column chromatography 35 
(MeOH/H2O 4/1, v/v) in 78% yield as a white solid (0.034 g, 0.0176 mmol). Mp: dec > 178 °C. 
1H NMR (400 36 
MHz, MeOD) δ (ppm): 6.71 (br, 8H ArH), 4.71 (s, 4H, H1), 4.53 (s, 4H, H2), 4.47 (d, J = 13.2 Hz, 4H, 37 
ArCHHaxAr), 3.98-3.86 (m, 24H, H6a,b, OCHHCH2CH2, OCH2CH2CH3), 3.71-3.63 (m, 16H, H3, OCHHCH2CH2, 38 
CHHNHCS), 3.58 (t, J = 9.6 Hz, 4H, H4), 3.29-3-27 (m, 4H, H5), 3.18 (d, J = 13.2 Hz, 4H, ArCHHeqAr), 2.08 (s, 39 
12H, NHCOCH3), 2.02-1.96 (m, 8H, OCH2CH2CH3), 1.86 (br, 8H, CH2CH2CH2), 1.06 (t, J = 6.8 Hz, 12H, 40 
OCH2CH2CH3). 
13C NMR (100 MHz, MeOD) δ (ppm): 179 (CS), 173.6 (NHCOCH3), 154.0 (CAr ipso), 135.32 (CAr 41 
ortho), 132.2 (CAr para), 123.9 (CAr), 99.5 (C1), 76.9 (C5), 76.8 (C6), 72.8 (C3), 67.3 (OCH2CH2CH2), 66.9 (C4), 42 
60.7 (OCH2CH2CH3), 53.6 (C2), 47.7 (CH2NHCS), 42.2 (C2), 30.5 (ArCH2Ar), 28.7 (CH2CH2CH2), 23.1 43 
(OCH2CH2CH3), 21.7 (NHCOCH3), 9.5 (OCH2CH2CH3). HRMS (ESI-TOF) m/z: calcd for C88H132N12O28S4Na 44 
[(1b+Na)+] 1955.8055, found 1955.8069. 45 
4.1.15.3. 5,11,17,23-Tetrakis-N-[3-(2-acetamido-2-deoxy-β-D-mannopiranosyloxy)-propyl-thioureido]-46 
25,26,27,28-tetrapropoxycalix[4]arene 1,3-Alternate (1c): 47 
Compound 1c was obtained after purification via C18 reverse phase column chromatography (MeOH/H2O 48 
3/2, v/v) as a white solid (0.023 g, 0.0119 mmol, 83%). Mp: dec > 176 °C. 1H NMR (400 MHz, MeOD) δ 49 
(ppm): 7.09 (s, 8H, ArH), 4.71 (s, 4H, H1), 4.56 (d, J = 3.6 Hz, 4H, H2), 4.06-3.94 (m, 4H, CHHNHCS), 3.87 (d, J 50 
= 3.2 Hz, 8H, H6ab), 3.83-3.64 (m, 24H, H3, OCH2CH2CH2, CHHNHCS, OCH2CH2CH3), 3.63-3.50 (m, 12H, 1 
ArCH2Ar, H4), 3.31-3.25 (m, 4H, H5), 2.10 (s, 12H, NHCOCH3), 2.01-1.81 (m, 8H, CH2CH2CH2), 1.96-1.80 (m, 2 
8H, OCH2CH2CH3), 1.04 (t, J = 7.6 Hz, 12H, OCH2CH2CH3). 
13C NMR (100 MHz, MeOD) δ (ppm): 180.7 (CS), 3 
173.5 (NHCOCH3), 153.9 (CAr ipso), 133.6 (CAr ortho), 131.6 (CAr para), 125.4 (CAr), 99.52 (C1), 76.90 (C5), 74.9 4 
(OCH2CH2CH3), 72.8 (C3), 67.2 (CH2NCS), 66.9 (C4), 60.7 (C6), 53.6 (C2), 42.2 (OCH2CH2CH2), 35.0 (ArCH2Ar), 5 
28.8 (CH2CH2CH2), 23.6 (OCH2CH2CH3), 21.6 (NHCOCH3), 9.7 (OCH2CH2CH3). HRMS (ESI-TOF) m/z: calcd for 6 
C88H132N12O28S4Na [(1c+Na)
+] 1955.8055, found 1955.8070. 7 
4.1.15.4. 5,11,17,23,29,35-Hexakis-N-[3-(2-acetamido-2-deoxy-β-D-mannopiranosyloxy)-propyl-8 
thioureido]-37,38,39,40,41,42-hexamethoxycalix[6]arene (1d): 9 
Purification by C18 reverse phase column chromatography (MeOH/H2O 64/36, v/v) afforded 1d in 54% yield 10 
as a off-white solid (0.015 g, 0.00549 mmol). Mp: 186-187 °C. 1H NMR (400 MHz, D2O, 80 °C) δ (ppm): 7.45 11 
(s, 12H, ArH), 5.20 (s, 6H, H1), 4.97 (d, J = 4.4 Hz, 6H, H2), 4.44 (br, 12H, ArCH2Ar), 4.40-4.23 (m, 24H, H3, 12 
H6a,b, OCHHCH2CH2), 4.18-4.11 (m, 6H, OCHHCH2CH2), 4.07-4.00 (m, 18H, CH2NHCS, H4), 3.84 (br, 6H, H5), 13 
3.77 (br, 18H, CH3), 2.52 (s, 18H, NHCOCH3), 2.31 (br, 12H, CH2CH2CH2). 
13C NMR (100 MHz, D2O, 80 °C) δ 14 
(ppm): 180.7 (CS), 175.4 (NHCOCH3), 154.8 (CAr ipso), 135.6 (CAr ortho), 134.1 (CAr para), 126.8 (CAr), 99.9 15 
(C1), 77.2 (C5), 75.0 (C3), 67.8 (C4), 67.7 (OCH2CH2CH2), 61.2 (OCH3), 59.9 (C6), 53.8 (C2), 42.5 (CH2NHCS), 30.7 16 
(CH2CH2CH2), 29.2 (ArCH2Ar), 22.8 (NHCOCH3). HRMS (ESI-TOF) m/z: calcd for C120H174N18O42S6K2 [(1d+2K)
2+] 17 
1404.6177, found 1404.6204. 18 
4.1.15.5. N-[3-( 2-acetamido-2-deoxy-β-D-mannopiranosyloxy)-propyl-thioureido]-4-propoxy-benzene (1-19 
MON): 20 
The pure product was obtained after purification by C18 reverse phase column chromatography 21 
(MeOH/H2O 1/1, v/v) as a off-white solid (0.0272 g, 0.0577 mmol, 66%). Mp: dec > 76 °C. 
1H NMR (400 22 
MHz, MeOD) δ (ppm): 7.24 (d, J = 8.9 Hz, 2H, ArH), 6.93 (d, J = 8.9 Hz, 2H, ArH), 4.65 (d, J = 1.5 Hz, 1H, H1), 23 
4.48 (dd, J2,1 =  1.5, J2,3 = 4.5 Hz, 1H, H2), 3.95 (t, J = 6.5 Hz, 2H, OCH2CH2CH3), 3.93-3.89 (m, 1H, 24 
OCHHCH2CH2), 3.88-3.84 (m, 1H, H6a,b), 3.69 (br, 1H, CHHNHCS), 3.67 (dd, J3,2 = 4.4, J3,4 = 9.6 Hz, 1H, H3), 25 
3.61 (m, 2H, OCHHCH2CH2, CHHNHCS), 3.53 (t, J = 9.6 Hz, 1H, H4), 3.29-3.23 (m, 1H, H5), 2.04 (s, 3H, 26 
NHCOCH3), 1.89-1.76 (m, 4H, OCH2CH2CH3, CH2CH2CH2), 1.06 (t, J = 7.2 Hz, 3H, OCH2CH2CH3). 
13C NMR (100 27 
MHz, MeOD) δ (ppm): 181.1 (CS), 173.5 (NHCOCH3), 157.7 (CAr ipso), 127.3 (CAr para), 126.7, 114.5 (CAr 28 
meta), 99.4 (C1), 76.9 (C5), 76.8 (OCH2CH2CH3), 69.4 (C4, OCH2CH2CH2), 60.6 (C6), 53.5 (C2), 41.9 (CH2NHCS), 29 
28.6 (CH2CH2CH2), 22.3 (OCH2CH2CH3), 21.4 (NHCOCH3), 9.4 (OCH2CH2CH3). HRMS (ESI-TOF) m/z: calcd for 30 
C21H33N3O7SNa [(7+Na)
+] 494.1937, found 494.1955. 31 
4.1.15.5. 5,11,17,23,29,35-Hexakis-N-[3-(2-acetamido-2-deoxy-β-D-mannopyranosyl-(14)-α-D-32 
glucopyranosyl-(12)-α-L-rhamnopyranosyloxy)-propyl-thioureido]-37,38,39,40,41,42-33 
hexamethoxycalix[6]arene (2a): 34 
The pure product was obtained after trituration in diethyl ether (7.5 mg, 0.00164 mmol, 80%). 1H NMR (400 35 
MHz, MeOD/D2O 75:25) δ (ppm): 8.49 (s, NH), 7.01 (br, 12H, ArH), 5.04 (br, OH), 4.94 (br, 6H, H1’), 4.87 (br, 36 
6H, H1’’), 4.85 (br, 6H, H1), 4.54 (br, 6H, H2’’), 4.14-3.22 (ovelapped, 144H, H3’’, H4’’, H5’’, H6a,b’’, H2’, H3’, H4’, H5’, 37 
H6,a,b’, H2, H3, H4, H5, OCH2CH2CH2, CH2NHCS, OCH3, ArCH2Ar), 2.08 (s, 18H, NHCOCH3), 1.86 (br, 12H, 38 
CH2CH2CH2), 1.29 (br, 18H, H6). 
13C NMR (100 MHz, MeOD/D2O 1:1) δ (ppm): 174.5, 99.4, 98.0, 97.7, 78.8, 39 
76.9, 76.8, 72.5, 72.3, 71.6, 71.5, 70.5, 70.1, 68.9, 66.7, 65.2, 60.4, 59.9, 53.5, 39.9, 28.7, 21.8, 16.8. HRMS 40 
(ESI-TOF)  m/z: calcd for C192H294N18O96S6Na3 [(2a+3Na)
3+] 1550.2248, found 1550.2276. 41 
4.1.15.6. 5,11,17,23,29,35-Hexakis-N-[3-(2-acetamido-2-deoxy-β-D-mannopyranosyl-(14)-α-D-42 
glucopyranosyl-(12)-β-L-rhamnopyranosyloxy)-propyl-thioureido]-37,38,39,40,41,42-43 
hexamethoxycalix[6]arene (2b): 44 
The pure product was obtained after trituration in diethyl ether (9.6 mg, 0.00209 mmol, 81%). 1H NMR (400 45 
MHz, MeOD/D2O 9:1) δ (ppm): 7.04 (br, 12H, ArH), 5,11 (br, 6H, H1’), 4.83 (s, 6H, H1’’), 4.67 (br, 6H, H1), 4.63 46 
(br, OH), 4.53 (br, 6H, H2’’), 4.24-3.27 (overlapped, 144H, H3’’, H4’’, H5’’, H6a,b’’, H2’, H3’, H4’, H5’, H6,a,b’, H2, H3, H4, 47 
H5, OCH2CH2CH2, CH2NHCS, OCH3, ArCH2Ar), 2.07 (s, 18H, NHCOCH3), 1.90 (br, 12H, CH2CH2CH2), 1.34 (br, 48 
18H, H6). 
13C NMR (100 MHz, MeOD/D2O 9:1) δ (ppm): 173.4, 100.7, 100.4, 99.5, 78.9, 78.4, 77.0, 72.9, 72.6, 49 
72.4, 72.1, 70.4, 66.7, 60.5, 60.0, 53.5, 29.5, 21.6, 16.8. HRMS (ESI-TOF) m/z: calcd for C192H294N18O96S6Na3 1 
[(2b+3Na)3+] 1550.2248, found 1550.2273. 2 
4.2. Competitive ELISA 3 
96-well flat-bottomed plates were incubated overnight at 4-8°C with a mixture of S. pneumoniae CPS 19F (1 4 
mg/mL,Sanofì-Aventis, France) and methylated human serum albumin (1 mg/mL). A solution of foetal calf 5 
serum (5%) in phosphate-buffered saline supplemented with Brij-35 (0.1%) and sodium azide (0.05%) was 6 
applied to the plates for blocking of nonspecific binding sites. The plates were incubated overnight at 4-8°C 7 
with a solution (1:200) of rabbit polyclonal anti-19F, used as reference serum (Statents serum Institute, 8 
Artillerivej, Denmark). When compounds were tested, they were added to each well immediately before 9 
the addition of the reference serum. The plates were then incubated with alkaline phosphatase conjugate 10 
goat anti-rabbit IgG (Sigma-Aldrich, Milan, Italy), stained with p-nitrophenylphosphate, and the absorbance 11 
was measured at 405 nm with an Ultramark microplate reader (Bio-Rad Laboratories S.r.l., Milan, Italy). 12 
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